Description
Understand FDA enforcement trends across pharmaceutical and medical device operations, identify recurring compliance deficiencies, and strengthen inspection readiness with ComplyFDA’s quarterly regulatory intelligence.
Combination products introduce complex regulatory challenges because drug and device constituent parts may be subject to different quality system requirements, manufacturing controls, and FDA oversight. ComplyFDA’s Combination Products Insider Intelligence Report brings pharmaceutical and medical device enforcement intelligence together in one comprehensive resource.
This quarterly report examines FDA warning letters, regulatory citation patterns, cGMP deficiencies, and quality system concerns to help organizations identify potential compliance vulnerabilities and prioritize risk-based improvements.
What’s Inside This Report?
- Combined FDA Enforcement Intelligence: Pharmaceutical and medical device citation trends, including historical comparisons of cGMP, packaging, labeling, and clinical enforcement activity.
- Pharmaceutical cGMP Analysis: Examination of frequently cited deficiencies under 21 CFR Part 211, including laboratory controls, aseptic processing, production procedures, contamination prevention, batch records, and quality unit oversight.
- Medical Device Quality System Intelligence: Analysis of device-related compliance deficiencies involving quality procedures, production controls, process validation, design controls, and documentation.
- QMSR and ISO 13485:2016 Citation Trends: Review of frequently cited medical device quality management requirements, including purchasing controls, product planning, design changes, and equipment control.
- Regulatory Citation Comparisons: Visual charts examining pharmaceutical and medical device enforcement patterns, quality system categories, and recurring compliance concerns.
- FDA Warning Letter Intelligence: Extensive listings of pharmaceutical and medical device warning letters to support regulatory surveillance, compliance benchmarking, and internal risk assessments.
- Regulatory Reference Resources: References covering 21 CFR Parts 211, 820, and 803, along with Medical Device Single Audit Program (MDSAP) resources.
Why This Intelligence Matters
For organizations developing or manufacturing combination products, regulatory compliance requires an understanding of pharmaceutical and medical device quality system expectations.
Quality Assurance Directors, Regulatory Affairs Professionals, Compliance Officers, R&D Leaders, Supplier Quality Engineers, and Manufacturing Executives can use this intelligence to:
- Identify recurring FDA enforcement concerns across pharmaceutical and medical device operations.
- Evaluate quality system weaknesses that may affect drug and device constituent parts.
- Prioritize internal audits, supplier oversight, process validation, and corrective actions.
- Support cross-functional regulatory risk assessments and inspection preparation.
- Monitor FDA citation patterns to inform compliance planning and quality system improvements.
Turn Regulatory Intelligence Into Action
Purchase ComplyFDA’s Combination Products FDA Insider Intelligence Quarterly Report to access pharmaceutical and medical device enforcement analysis, FDA warning letter intelligence, and documented quality system deficiencies in one consolidated report.
Strengthen regulatory oversight, support informed compliance decisions, and prepare your organization for FDA inspection scrutiny.
